arrow
M

Mingzhu Zhu

novavax
H指数:27
被引数:4,242

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Validation of a Mucosal IgA Assay for SARS-CoV-2

SARS-CoV-2黏膜IgA检测方法的验证

2026-05-200
OAAI
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2 Omicron JN.1 and LP.8.1 Subvariant Lineage Strains with Homologous and Heterologous Matched Sera in Clinically Relevant Samples

验证同源和异源匹配血清在临床相关样本中针对严重急性呼吸综合征冠状病毒2奥密克戎JN.1和LP.8.1亚变体谱系毒株的假病毒中和试验

2026-05-050
OA
Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform–specific priming and immune imprinting

抗刺突蛋白IgG4和Fc效应反应:SARS-CoV-2疫苗平台特异性初始免疫和免疫印记的影响

2025-06-260
OA
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study

一种单价奥密克戎XBB.1.5 SARS-CoV-2重组刺突蛋白疫苗在既往未接种疫苗、SARS-CoV-2血清阳性的受试者中的免疫原性和安全性:一项开放标签2/3期研究的第28天主要分析

VACCINE
IF3.5
2025-05-010
OAAI
Safety and immunogenicity of Omicron protein vaccines in mRNA vaccinated adolescents: A phase 3, randomised trial-

奥密克戎蛋白疫苗在mRNA疫苗接种青少年中的安全性与免疫原性:一项III期随机试验

2025-02-010
OAAI
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M™ adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial
2024-12-120
OAAI
A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine
2024-11-190
OAAI
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
2024-06-012
OAAI
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial

异源Omicron BA.1和二价SARS-CoV-2重组刺突蛋白加强疫苗的免疫原性和安全性: 一项3期随机临床试验

2023-11-162
OAAI
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
2022-11-0152
OAAI